elbion AG Increases Series A Financing to EUR35 Million
"We are extremely pleased that this financing provides us with adequate resources to swiftly progress our clinical and pre-clinical development programs. With AWD 12-281 and ELB139 already in clinical Phase II we have the potential to generate proof of concept in man in the first half of 2006. Further, ELB353 and ELB526 are drug candidates that are intended to enter the clinic in 2006 as well" said elbion's CEO, Bernd Kastler, and added: "Our top tier financial investor base - together with our strong product portfolio - gives us the chance to evaluate a variety of strategic options in the forthcoming months."
As a result of the transaction, Dr. Christoph Schroeder, Senior Advisor at TVM in Munich, has joined elbion's Supervisory Board.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.